DATA5m-LM4 | SSTR antagonist | ligand

MedKoo Cat#: 127317 | Name: DATA5m-LM4

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DATA5m-LM4 is a SSTR antagonist and ligand for making radio-labled G68. [68Ga]Ga-DATA5m-LM4 is a PET Radiotracer in the Diagnosis of SST2R-Positive Tumors. DATA5m-LM4 displayed high SST2R binding affinity. [68Ga]Ga-DATA5m-LM4 accurately visualized tumor lesions with high contrast on PET/CT. [68Ga]Ga-DATA5m-LM4 has shown excellent prospects for the PET/CT diagnosis of SST2R-positive tumors.

Chemical Structure

DATA5m-LM4

CAS#N/A

Theoretical Analysis

MedKoo Cat#: 127317

Name: DATA5m-LM4

CAS#: N/A

Chemical Formula: C69H93ClN16O18S2

Exact Mass: 1532.5984

Molecular Weight: 1534.17

Elemental Analysis: C, 54.02; H, 6.11; Cl, 2.31; N, 14.61; O, 18.77; S, 4.18

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

DATA5m-LM4; DATA5mLM4; DATA5m LM4

IUPAC/Chemical Name

2,2'-(6-(5-((1-(((4R,7S,10S,13R,16S,19R)-4-(((R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)carbamoyl)-10-(4-aminobutyl)-7-((S)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-16-(pyridin-4-ylmethyl)-13-(4-ureidobenzyl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-yl)amino)-3-(4-chlorophenyl)-1-oxopropan-2-yl)amino)-5-oxopentyl)-6-((carboxymethyl)(methyl)amino)-1,4-diazepane-1,4-diyl)diacetic acid

InChi Key

BMRIQCSDCVSPMH-ZUDGYNLLSA-N

InChi Code

InChI=1S/C69H93ClN16O18S2/c1-40(87)59-67(103)82-54(65(101)78-49(60(72)96)29-43-13-19-47(88)20-14-43)37-106-105-36-53(66(102)80-52(32-44-21-25-74-26-22-44)64(100)79-51(31-42-11-17-46(18-12-42)75-68(73)104)63(99)77-48(61(97)83-59)7-4-6-24-71)81-62(98)50(30-41-9-15-45(70)16-10-41)76-55(89)8-3-5-23-69(84(2)33-56(90)91)38-85(34-57(92)93)27-28-86(39-69)35-58(94)95/h9-22,25-26,40,48-54,59,87-88H,3-8,23-24,27-39,71H2,1-2H3,(H2,72,96)(H,76,89)(H,77,99)(H,78,101)(H,79,100)(H,80,102)(H,81,98)(H,82,103)(H,83,97)(H,90,91)(H,92,93)(H,94,95)(H3,73,75,104)/t40-,48-,49+,50?,51+,52-,53-,54-,59-/m0/s1

SMILES Code

OC(CN1CC(CN(CC(O)=O)CC1)(CCCCC(NC(CC2=CC=C(Cl)C=C2)C(N[C@H](C(N[C@@H](CC3=CC=NC=C3)C(N[C@H](CC4=CC=C(NC(N)=O)C=C4)C(N[C@@H](CCCCN)C(N[C@@H]([C@H](C)O)C5=O)=O)=O)=O)=O)CSSC[C@H](N5)C(N[C@H](CC6=CC=C(O)C=C6)C(N)=O)=O)=O)=O)N(CC(O)=O)C)=O

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,534.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Viswanathan R, Ballal S, Yadav MP, Roesch F, Sheokand P, Satapathy S, Tripathi M, Agarwal S, Moon ES, Bal C. Head-to-Head Comparison of SSTR Antagonist [68Ga]Ga-DATA5m-LM4 with SSTR Agonist [68Ga]Ga-DOTANOC PET/CT in Patients with Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Imaging Study. Pharmaceuticals (Basel). 2024 Feb 22;17(3):275. doi: 10.3390/ph17030275. PMID: 38543061; PMCID: PMC10974918.